FORM 51-102F3
MATERIAL CHANGE REPORT
Item 1.Name and Address of Company
BIOHARVEST SCIENCES INC.
Suite 1140 – 625 Howe Street
Vancouver, BC, V6C 2T6
(the “Company” or “BioHarvest”)
Item 2.Date of Material Change
September 8, 2026
Item 3.News Release
The news release (the “News Release”) was issued on September 3, 2026 and disseminated by Newsfile Corp.
Item 4.Summary of Material Change
The Company announced its intention to register its common shares without par value (the “Common Shares”) on the Tel Aviv Stock Exchange (TASE) and to become dual-listed for trade on both the Nasdaq and TASE markets. The Company’s Common Shares began trading on the TASE on September 8, 2026.
Item 5.Full Description of Material Change
On September 3, 2026, Company announced its intention to register all its outstanding Common Shares on the Tel Aviv Stock Exchange (TASE) and to become dual-listed for trade on both the Nasdaq and TASE markets.
The Company’s Common Shares began trading on the TASE on September 8, 2026.
Per the filed registration documents, the Company requested to register Common Shares for dual listing on the TASE, including:
(1) all 22,667,842 outstanding Common Shares;
(2) up to 4,516,021 Common Shares available for future issuance to officers, employees and consultants of the Company pursuant to the Company's equity incentive plan, out of which 2,564,876 options to purchase Common Shares and 269,521 restricted shares units are currently outstanding and 1,681,624 Common Shares remain available for future grants (upon exercise of options and restricted share units); and
(3) 610,742 Common Shares issuable upon exercise of 610,742 warrants granted to investors.
The Common Shares are listed for trading in the United States on the Nasdaq Capital Market and as of September 8, 2026 are also listed for trading on the TASE, under the English symbol BHST and the alternative Hebrew symbol "".
All future EDGAR filings will simultaneously be filed on MAGNA Disclosure System.
Item 6.Reliance on Subsection 7.1(2) of National Instrument 51-102
Not applicable.
Item 7.Omitted Information
None.
Item 8.Executive Officer
For further information, please contact:
David Ryan
Secretary and VP, Investor Relations
604 622-1187
Item 9.Date of Report
September 15, 2026.